AZense Journal Club
by Azense Medical Education
Journal Club E64: Retatrutide: The 28% Drug That Is Not Approved Yet
About this podcast
AZense Journal Club is a clinical education podcast for residents, hospitalists, PAs, NPs, and practicing clinicians. Episodes use AI-generated voices and physician-reviewed educational scripts from Azense Medical Education, an Azense AI LLC educational project. Each episode breaks down a recent or landmark trial with a practical hospital medicine lens. For clinical education only, not individual medical advice.
Episodes
The newest 20 of 65 episodes
- Journal Club E64: Retatrutide: The 28% Drug That Is Not Approved Yet · 7 min · Season 1 Episode 64A triple GIP, GLP-1, and glucagon agonist with striking phase 2 and phase 3 signals — and a real hospitalist problem when patients obtain unapproved products outside trials.
- Journal Club E63: The One-Bag Fix: Zoledronic Acid After the Fracture That Almost Wasn't Treated · 9 min · Season 1 Episode 63HORIZON proved that annual intravenous zoledronic acid after a hip fracture reduces new clinical fractures and all-cause mortality. What it did not test is timing. No randomized…
- Journal Club E62: The Fluid Wars: Balanced Crystalloids vs Saline, and the WATERFALL Reset · 10 min · Season 1 Episode 62Saline is not physiologic, but the outcome differences are small and context-dependent. SALT-ED and SMART favor balanced crystalloids by about one percentage point on kidney…
- Journal Club E61: Finerenone Beyond Diabetes: The 2026 CKD Evidence Reset · 11 min · Season 1 Episode 61A 2026 wave of trials moves finerenone from a diabetic-kidney drug toward a broad cardiorenal agent. FIND-CKD is the first Phase 3 win in non-diabetic CKD, but the glomerular…
- Journal Club E60: Suzetrigine: A New Class of Pain Relief, Minus the Hype · 6 min · Season 1 Episode 60Suzetrigine (Journavx) is the first genuinely new pharmacologic class of pain medicine since the COX-2 inhibitors. It beat placebo and carries no addiction liability, but it did…
- Journal Club E59: The LRINEC Illusion: Why a Score Can't Rule Out Necrotizing Fasciitis · 7 min · Season 1 Episode 59The LRINEC score looked near-perfect in 2004, but twenty years of external validation show it misses roughly one in three necrotizing soft tissue infections. Why a low score must…
- Journal Club E58: Corticosteroids for Severe Community-Acquired Pneumonia: What the 2023-2026 Trials and Meta-Analyses Actually Show · 15 min · Season 1 Episode 58After the positive CAPE COD trial and the messy, neutral REMAP-CAP result, does hydrocortisone still reduce mortality and mechanical ventilation in severe CAP, and in whom?
- Journal Club E57: Colchicine in Coronary Artery Disease: What the Trials and 2025 Meta-Analyses Actually Show · 8 min · Season 1 Episode 57After the neutral CLEAR-SYNERGY trial, does low-dose colchicine still have a role in chronic coronary disease and after acute coronary syndrome?
- Journal Club E56: VANISH2: First-Line Catheter Ablation vs Antiarrhythmic Drugs for VT in Ischemic Cardiomyopathy · 10 min · Season 1 Episode 56In prior-MI patients with an ICD and ventricular tachycardia who have not failed drug therapy, is first-line catheter ablation better than antiarrhythmic drugs?
- Journal Club E55: EARLY TAVR: Transcatheter Valve Replacement vs Surveillance in Asymptomatic Severe Aortic Stenosis · 10 min · Season 1 Episode 55In truly asymptomatic severe aortic stenosis with preserved ejection fraction, does early transcatheter aortic valve replacement beat watchful waiting?
- Journal Club E54: PEERLESS: Large-Bore Thrombectomy vs Catheter-Directed Thrombolysis for Intermediate-Risk PE · 10 min · Season 1 Episode 54In intermediate-high risk pulmonary embolism, is large-bore mechanical thrombectomy superior to catheter-directed thrombolysis for preventing deterioration and bleeding?
- Journal Club E53: The 4D Trial: Dexmedetomidine for Hyperactive Delirium in Non-Intubated ICU Patients · 8 min · Season 1 Episode 53In non-intubated ICU patients with hyperactive delirium, does dexmedetomidine shorten delirium duration compared with placebo, without the respiratory depression of standard…
- Journal Club E52: CONCERN: AI Early Warning for Inpatient Deterioration · 8 min · Season 1 Episode 52Can an AI early warning system built from nursing surveillance documentation improve hospital ward outcomes, or does it just create more alerts?
- Journal Club E51: SCD-PROTECT: Wearable Defibrillators in the Early High-Risk Window · 8 min · Season 1 Episode 51In adults with newly reduced LVEF from non-ischaemic cardiomyopathy or recent myocardial infarction on contemporary 4-pillar GDMT, what is the rate of life-threatening…
- Journal Club E50: BigpAK-2: Biomarker-Guided Care to Prevent Acute Kidney Injury After Major Surgery · 8 min · Season 1 Episode 50In adults at increased risk of acute kidney injury after major noncardiac surgery, does urinary biomarker-triggered application of the Kidney Disease Improving Global Outcomes…
- Journal Club E49: Female Hospitalists and Patient Outcomes: Do Physician Characteristics Matter? · 7 min · Season 1 Episode 49Do patients of female physicians have different mortality and readmission rates compared to patients of male physicians?
- Journal Club E48: PAGODA: Perioperative Gabapentin Does Not Help, and Sometimes Hurts · 7 min · Season 1 Episode 48In opioid-naive adults undergoing major noncardiac surgery, does routine perioperative gabapentin or pregabalin reduce opioid use and pain without unacceptable harms?
- Journal Club E47: SURPASS-CVOT: Tirzepatide Is at Least as Good as Dulaglutide for Heart Disease in Type 2 Diabetes · 8 min · Season 1 Episode 47Is tirzepatide non-inferior to dulaglutide for MACE prevention in T2DM with established CVD?
- Journal Club E46: ATTIRE: Giving Albumin to Hospitalized Cirrhosis Patients Does Not Help · 7 min · Season 1 Episode 46Does targeting albumin infusions to maintain levels >=30 g/L reduce complications in hospitalized cirrhosis patients?
- Journal Club E45: Early Paracentesis in Cirrhosis: Don't Wait to Tap · 7 min · Season 1 Episode 45Does early diagnostic paracentesis (within 12-24h of admission) improve outcomes in hospitalized cirrhosis patients with ascites?








